K
Kurt Van der Speeten
Researcher at University of Hasselt
Publications - 47
Citations - 1851
Kurt Van der Speeten is an academic researcher from University of Hasselt. The author has contributed to research in topics: Hyperthermic intraperitoneal chemotherapy & Medicine. The author has an hindex of 14, co-authored 39 publications receiving 1421 citations. Previous affiliations of Kurt Van der Speeten include Transnational University Limburg.
Papers
More filters
Journal ArticleDOI
Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Terence C. Chua,B. J. Moran,Paul H. Sugarbaker,Edward A. Levine,Olivier Glehen,François Noël Gilly,Dario Baratti,Marcello Deraco,Dominique Elias,Armando Sardi,Winston Liauw,Tristan D. Yan,P. Barrios,Alberto Gomez Portilla,Ignace H J T de Hingh,Wim Ceelen,Joerg O.W. Pelz,Pompiliu Piso,Santiago González-Moreno,Kurt Van der Speeten,David L. Morris +20 more
TL;DR: The combined modality strategy for PMP may be performed safely with acceptable morbidity and mortality in a specialized unit setting with 63% of patients surviving beyond 10 years with Optimal cytoreduction achieves the best outcomes.
Journal ArticleDOI
The Treatment of Peritoneal Carcinomatosis of Colorectal Cancer with Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Peroperative Chemotherapy (HIPEC) with Oxaliplatin: A Belgian Multicentre Prospective Phase II Clinical Study
Daphne Hompes,André D'Hoore,Eric Van Cutsem,Steffen Fieuws,Wim Ceelen,Marc Peeters,Kurt Van der Speeten,Claude Bertrand,Hugues Legendre,Joseph Kerger +9 more
TL;DR: Only after dichotomizing PC index was a significant difference in OS found between low and high PC index found, and CCRS followed by HIPEC with oxaliplatin for PC from CRC can be implemented with acceptable morbidity.
Journal ArticleDOI
Pathophysiology of colorectal peritoneal carcinomatosis: Role of the peritoneum.
TL;DR: Current data regarding the molecular mechanisms underlying the development of colorectal PC are reviewed, with a special focus on the peritoneum and the role of the surgeon in peritoneal disease spread.
Journal ArticleDOI
Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy.
TL;DR: This review aims to clarify the pharmacokinetic and pharmacodynamic data currently available regarding the intraperitoneal delivery of cancer chemotherapy agents in patients with peritoneal carcinomatosis.
Journal ArticleDOI
Surgical technology and pharmacology of hyperthermic perioperative chemotherapy.
TL;DR: As the management of peritoneal metastases has progressed over three decades, early cases are now seen in which a laparoscopic CRS and HIPEC may be appropriate and prophylactic use of Laparoscopic HIPEC with perforated appendiceal malignancies and T4 colon cancers may beappropriate.